Table 2 Outcome of TACE before and after propensity score matching analysis in UICC T3 HCC patients
Variables | Before PSM | After PSM |
|---|---|---|
TACE (n = 899) | TACE (n = 244) | |
Procedures (mean ± SD) | 1.8 ± 1.2 | 1.9 ± 1.2 |
1 procedure | 457 (50.8) | 118(48.3) |
2–3 procedures | 365 (40.6) | 103(42.2) |
more than 3 procedures | 77 (8.6) | 23(9.4) |
Best tumor response, n (%) | Â | Â |
CR | 18 (2.0) | 6 (2.5) |
PR | 203 (22.6) | 56 (23.0) |
SD | 259 (28.8) | 73 (29.9) |
DCR (CR + PR + SD) | 480 (53.4) | 135 (55.3) |
Median TTP (95%CI) months | 5.7(4.7–6.6) | 7.7 (5.7–9.8) |
Cases of PD, n (%) | 419 (46.6) | 109 (44.7) |
Patterns of PD | Â | Â |
Enlarged or new lesion (n, %) | 186 (20.7) | 49 (20.1) |
Metastasis or vessel invasion (n, %) | 233 (25.9) | 60 (24.6) |
Treatment after TACE | Â | Â |
Heat ablation (n, %) | 135 (15.0) | 43 (17.6) |
Resection (n, %) | 93 (10.3) | 27 (11.1) |
Sorafenib (n, %) | 86 (9.6) | 21 (8.6) |